Cardiovascular

Although mortality rates for cardiovascular diseases declined consistently over the decade 1998-2008, heart disease and stroke are still the number one killer in the US. This fact that illustrates why cardiovascular drugs and therapeutics is such a key sector of the pharmaceutical industry.

The reports, books, and subscriptions listed under Research and Markets’ Cardiovascular category explore in-depth vital areas such as the latest clinical trials for treatments for a variety of afflictions such as hypertension, arrhythmia and stroke. Learn all the latest news about products and R&D of pharmaceutical companies, hospitals and universities, as well as the latest market trends in a wide selection of countries. Also featured is a selection of academic and clinical textbooks for those working at the coalface of cardiovascular pharmaceuticals. Show Less ... more

• Refractory Angina - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Nov 2011 , Pages: 20
  Refractory Angina - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Refractory Angina - Pipeline Review, H2 2011', provides an overview of the Refractory Angina therapeutic pipeline. This...

• Post-Myocardial Infarction - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Nov 2011 , Pages: 29
  Post-Myocardial Infarction - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Post-Myocardial Infarction - Pipeline Review, H2 2011', provides an overview of the Post-Myocardial Infarction...

• Vasculitis - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Nov 2011 , Pages: 48
  Vasculitis - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Vasculitis - Pipeline Review, H2 2011', provides an overview of the Vasculitis therapeutic pipeline. This report provides information...

• Raynauds Disease - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Nov 2011 , Pages: 36
  Raynauds Disease - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Raynauds Disease - Pipeline Review, H2 2011', provides an overview of the Raynauds Disease therapeutic pipeline. This...

• The Impact of Cardiac Safety on the Regulatory Landscape: Recent Case Studies

  EURO€ 1,768.00USD$ 2,300.00GBP£ 1,487.00AUD$ 2,250.00JPY¥ 227,086.00SEK 15 101,00CHF 2'168.00CAD$ 2,344.00 Decision Resources, Inc, Nov 2011
  Adverse cardiovascular events are one of the leading causes of drug withdrawal or restriction; drugs spanning multiple therapeutic areas have been implicated in these major adverse events, and recent...

• Cardiovascular Inflammation Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Nov 2011 , Pages: 82
  Cardiovascular Inflammation Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Cardiovascular Inflammation Global Clinical Trials Review, H2, 2011" provides data...

• Acute Heart Failure Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Nov 2011 , Pages: 90
  Acute Heart Failure Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Acute Heart Failure Global Clinical Trials Review, H2, 2011" provides data on the Acute Heart...

• Vascular Dysfunction Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Nov 2011 , Pages: 80
  Vascular Dysfunction Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Vascular Dysfunction Global Clinical Trials Review, H2, 2011" provides data on the Vascular...

• Endocarditis Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Nov 2011 , Pages: 65
  Endocarditis Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Endocarditis Global Clinical Trials Review, H2, 2011" provides data on the Endocarditis clinical trial...

• Abdominal Aortic Aneurysms Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Nov 2011 , Pages: 74
  Abdominal Aortic Aneurysms Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Abdominal Aortic Aneurysms Global Clinical Trials Review, H2, 2011" provides data on...

• Dilated Cardiomyopathy Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Nov 2011 , Pages: 79
  Dilated Cardiomyopathy Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Dilated Cardiomyopathy Global Clinical Trials Review, H2, 2011" provides data on the Dilated...

• Left Ventricular Hypertrophy Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Nov 2011 , Pages: 86
  Left Ventricular Hypertrophy Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Left Ventricular Hypertrophy Global Clinical Trials Review, H2, 2011" provides data...

• Global Cardiovascular Monitoring & Diagnostic Devices Market (2011 - 2016)

  EURO€ 2,921.00USD$ 3,800.00GBP£ 2,457.00AUD$ 3,717.00JPY¥ 375,185.00SEK 24 950,00CHF 3'582.00CAD$ 3,872.00 Transparency Market Research, Nov 2011 , Pages: 108
  Cardiovascular devices are used in treating diseases related to the heart and the circulatory system It also includes the devices such as interventional cardiology, cardiac rhythm management, cardiac...

• Cerebral Aneurysms Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Nov 2011 , Pages: 53
  Cerebral Aneurysms Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Cerebral Aneurysms Global Clinical Trials Review, H2, 2011" provides data on the Cerebral Aneurysms...

• Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

  EURO€ 2,690.00USD$ 3,500.00GBP£ 2,263.00AUD$ 3,423.00JPY¥ 345,565.00SEK 22 980,00CHF 3'299.00CAD$ 3,566.00 GlobalData, Nov 2011 , Pages: 87
  Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Summary GlobalData, the industry analysis specialist, has released its new report, “Heart Failure (HF) Therapeutics...

• Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2018

  EURO€ 2,690.00USD$ 3,500.00GBP£ 2,263.00AUD$ 3,423.00JPY¥ 345,565.00SEK 22 980,00CHF 3'299.00CAD$ 3,566.00 GlobalData, Nov 2011 , Pages: 89
  Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Summary GlobalData, the industry analysis specialist, has released its new report, “Anti-Hypertension Therapeutics...

• Cardiac Marker Diagnostic Testing Markets

  EURO€ 2,613.00USD$ 3,400.00GBP£ 2,199.00AUD$ 3,325.00JPY¥ 335,692.00SEK 22 324,00CHF 3'205.00CAD$ 3,465.00 TriMark Publications, Nov 2011 , Pages: 139
  Cardiac marker diagnostic testing measures the concentration of certain proteins, i e , biomarkers, which indicate the presence or severity of cardiovascular disease (CVD) Among the most prevalent CVDs...

• Critical Limb Ischemia - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Oct 2011 , Pages: 86
  Critical Limb Ischemia - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Critical Limb Ischemia - Pipeline Review, H2 2011', provides an overview of the Critical Limb Ischemia therapeutic...

• Diabetic Hypertension - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Oct 2011 , Pages: 17
  Diabetic Hypertension - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Diabetic Hypertension - Pipeline Review, H2 2011', provides an overview of the Diabetic Hypertension therapeutic...

• Angina (Angina Pectoris) - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Oct 2011 , Pages: 61
  Angina (Angina Pectoris) - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Angina (Angina Pectoris) - Pipeline Review, H2 2011', provides an overview of the Angina (Angina Pectoris) therapeutic...

• Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Oct 2011 , Pages: 62
  Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2011', provides an overview of the Deep Vein Thrombosis (DVT)...

• Arrhythmias - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Oct 2011 , Pages: 38
  Arrhythmias - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Arrhythmias - Pipeline Review, H2 2011', provides an overview of the Arrhythmias therapeutic pipeline. This report provides...

• Cardiac Rhythm Management Devices World Markets

  EURO€ 2,613.00USD$ 3,400.00GBP£ 2,199.00AUD$ 3,325.00JPY¥ 335,692.00SEK 22 324,00CHF 3'205.00CAD$ 3,465.00 TriMark Publications, Oct 2011 , Pages: 250
  In the last five decades, electronic cardiac medicine has witnessed dramatic technological developments The cardiac rhythm management products mainly marketed by a handful of global players are used...

• European Society of Cardiology Congress 2011 - Post-Conference Review and Analysis

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Sep 2011 , Pages: 26
  European Society of Cardiology Congress 2011 - Post-Conference Review and Analysis Summary GlobalData, the industry analysis specialist, has released its new conference alerts, “European Society of...

• Aortic Valve Diseases Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Sep 2011 , Pages: 65
  Aortic Valve Diseases Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Aortic Valve Diseases Global Clinical Trials Review, H2, 2011" provides data on the Aortic...

• Sick Sinus Syndrome Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Sep 2011 , Pages: 58
  Sick Sinus Syndrome Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Sick Sinus Syndrome Global Clinical Trials Review, H2, 2011" provides data on the Sick Sinus...

• Hypoplastic Left Heart Syndrome Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Sep 2011 , Pages: 52
  Hypoplastic Left Heart Syndrome Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Hypoplastic Left Heart Syndrome Global Clinical Trials Review, H2, 2011" provides...

• Raynauds Disease Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Sep 2011 , Pages: 66
  Raynauds Disease Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Raynauds Disease Global Clinical Trials Review, H2, 2011" provides data on the Raynauds Disease...

• Coronary Thrombosis Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Sep 2011 , Pages: 56
  Coronary Thrombosis Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Coronary Thrombosis Global Clinical Trials Review, H2, 2011" provides data on the Coronary...

• Tetralogy Of Fallot Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Sep 2011 , Pages: 51
  Tetralogy Of Fallot Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Tetralogy Of Fallot Global Clinical Trials Review, H2, 2011" provides data on the Tetralogy...

• Atrial Septal Defect Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Sep 2011 , Pages: 55
  Atrial Septal Defect Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Atrial Septal Defect Global Clinical Trials Review, H2, 2011" provides data on the Atrial...

• Acute Heart Failure - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Sep 2011 , Pages: 58
  Acute Heart Failure - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Acute Heart Failure - Pipeline Review, H2 2011', provides an overview of the Acute Heart Failure therapeutic pipeline....

• Hypertension - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Sep 2011 , Pages: 134
  Hypertension - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Hypertension - Pipeline Review, H2 2011', provides an overview of the Hypertension therapeutic pipeline. This report provides...

• Atrial Fibrillation - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Sep 2011 , Pages: 92
  Atrial Fibrillation - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Atrial Fibrillation - Pipeline Review, H2 2011', provides an overview of the Atrial Fibrillation therapeutic pipeline....

• Acute Coronary Syndrome - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Sep 2011 , Pages: 106
  Acute Coronary Syndrome - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Acute Coronary Syndrome - Pipeline Review, H2 2011', provides an overview of the Acute Coronary Syndrome therapeutic...

• Peripheral Arterial Disease - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Sep 2011 , Pages: 132
  Peripheral Arterial Disease - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Peripheral Arterial Disease - Pipeline Review, H2 2011', provides an overview of the Peripheral Arterial Disease...

• Venous Thromboembolism - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Sep 2011 , Pages: 95
  Venous Thromboembolism - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Venous Thromboembolism - Pipeline Review, H2 2011', provides an overview of the Venous Thromboembolism therapeutic...

• High Triglyceridemia Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Sep 2011 , Pages: 99
  High Triglyceridemia Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “High Triglyceridemia Global Clinical Trials Review, H2, 2011" provides data on the High Triglyceridemia...

• Left Ventricular Dysfunction Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Sep 2011 , Pages: 140
  Left Ventricular Dysfunction Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Left Ventricular Dysfunction Global Clinical Trials Review, H2, 2011" provides data...

• Coronary Vasospasm Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Sep 2011 , Pages: 52
  Coronary Vasospasm Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Coronary Vasospasm Global Clinical Trials Review, H2, 2011" provides data on the Coronary Vasospasm...

• Ventricular Arrhythmia Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Sep 2011 , Pages: 79
  Ventricular Arrhythmia Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Ventricular Arrhythmia Global Clinical Trials Review, H2, 2011" provides data on the Ventricular...

• Low Cardiac Output Syndrome Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Sep 2011 , Pages: 67
  Low Cardiac Output Syndrome Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Low Cardiac Output Syndrome Global Clinical Trials Review, H2, 2011" provides data...

• Pre-Eclampsia Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Sep 2011 , Pages: 87
  Pre-Eclampsia Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Pre-Eclampsia Global Clinical Trials Review, H2, 2011" provides data on the Pre-Eclampsia clinical...

• Global Cardiovascular Drug Market: Strategic Assessments of Leading Suppliers

  EURO€ 7,533.00USD$ 9,800.00GBP£ 6,338.00AUD$ 9,585.00JPY¥ 967,583.00SEK 64 345,00CHF 9'237.00CAD$ 9,986.00 Venture Planning Group (VPG), Sep 2011
  This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global Cardiovascular Drug Market. The report provides a worldwide...

• Cardiogenic Shock Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Aug 2011 , Pages: 67
  Cardiogenic Shock Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Cardiogenic Shock Global Clinical Trials Review, H2, 2011" provides data on the Cardiogenic Shock...

• Heart Transplantation Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Aug 2011 , Pages: 102
  Heart Transplantation Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Heart Transplantation Global Clinical Trials Review, H2, 2011" provides data on the Heart...

• Pulmonary Arterial Hypertension - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Aug 2011 , Pages: 120
  Pulmonary Arterial Hypertension - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Pulmonary Arterial Hypertension - Pipeline Review, H2 2011', provides an overview of the Pulmonary Arterial...

• Left Ventricular Hypertrophy - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Aug 2011 , Pages: 32
  Left Ventricular Hypertrophy - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Left Ventricular Hypertrophy - Pipeline Review, H2 2011', provides an overview of the Left Ventricular Hypertrophy...

• Restenosis - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Aug 2011 , Pages: 59
  Restenosis - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Restenosis - Pipeline Review, H2 2011', provides an overview of the Restenosis therapeutic pipeline. This report provides information...

• Heart Failure - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Aug 2011 , Pages: 133
  Heart Failure - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Heart Failure - Pipeline Review, H2 2011', provides an overview of the Heart Failure therapeutic pipeline. This report provides...